Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Arginine

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    147 result(s) found for: Arginine. Displaying page 1 of 8.
    1  2  3  4  5  6  7  8  Next»
    EudraCT Number: 2006-001852-11 Sponsor Protocol Number: ARG1 Start Date*: 2006-10-13
    Sponsor Name:Medical University of Vienna
    Full Title: Influence of L-Arginine on perfusion in patients receiving peripheral bypass surgery (Einfluss von L-Arginin auf die Perfusion bei Patienten mit peripheren Bypassoperationen)
    Medical condition: In general, ischemia and reperfusion are main causes for tissue damage and consequently for organ damage after surgery. Particularily, patients suffering from a peripheral occlusive disease show a ...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2006-005421-31 Sponsor Protocol Number: Start Date*: 2007-04-24
    Sponsor Name:RER Saint Denis
    Full Title: Effets hémodynamiques de l’administration de vasopressine au décours de l’Arrêt Cardio-Respiratoire chez des patients en état de choc réfractaire Hemodynamic effects of vasopressin administration i...
    Medical condition: Patients admitted in ICU after sucessfully resuscitated cardiac arrest and developping a refractory shock
    Disease: Version SOC Term Classification Code Term Level
    8.1 10047146 Vasopressin LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-002674-36 Sponsor Protocol Number: 49929 Start Date*: 2017-10-12
    Sponsor Name:
    Full Title: DOES ARGININE ENHANCE GALACTOSE OXIDATIVE CAPACITY IN CLASSIC GALACTOSEMIA? A PILOT STUDY
    Medical condition: Classic galactosemia
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2014-001733-86 Sponsor Protocol Number: 1710 Start Date*: 2014-10-15
    Sponsor Name:Maastricht University
    Full Title: The effect of L-arginine on brown adipose tissue metabolism in South Asian and white Caucasian subjects
    Medical condition: Obesity, glucose intolerance, endothelial dysfunction
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-004775-40 Sponsor Protocol Number: APD334-202EU Start Date*: 2021-05-11
    Sponsor Name:Arena Pharmaceuticals Inc.
    Full Title: A Multicenter, Randomized, Double-Blind, Parallel-Group Study to Assess the Efficacy and Safety of Oral Etrasimod as Induction and Maintenance Therapy for Moderately to Severely Active Crohn’s Disease
    Medical condition: Crohn's Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10017947 - Gastrointestinal disorders 10011401 Crohn's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned) DE (Trial now transitioned) FR (Trial now transitioned) DK (Trial now transitioned) SK (Trial now transitioned) LT (Completed) LV (Completed) HU (Trial now transitioned) CZ (Trial now transitioned) PT (Prematurely Ended) NO (Completed) BE (Trial now transitioned) BG (Trial now transitioned) ES (Ongoing) HR (Trial now transitioned) IT (Trial now transitioned) RO (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-014437-24 Sponsor Protocol Number: P090203 Start Date*: 2009-09-23
    Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
    Full Title: Essai randomisé d'immunonutrition par L-arginine guidée en réanimation non chirurgicale
    Medical condition: Patients de réanimation non chirurgicale sous ventilation artificielle, non immunodéprimés
    Disease: Version SOC Term Classification Code Term Level
    8.1 10062733 Nutritional supplement PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-003226-23 Sponsor Protocol Number: APD334-206 Start Date*: 2021-02-02
    Sponsor Name:Arena Pharmaceuticals Inc.
    Full Title: A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Etrasimod in Adult Subjects with Eosinophilic Esophagitis
    Medical condition: Eosinophilic Esophagitis (EoE)
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004856 10064220 Eosinophilic esophagitis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed) NL (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2017-003851-45 Sponsor Protocol Number: CAEB1102-101A Start Date*: 2018-03-14
    Sponsor Name:Aeglea Biotherapeutics, Inc.
    Full Title: A Phase 1/2 Open-label Study in Patients with Arginase I Deficiency to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of Intravenous AEB1102
    Medical condition: Arginase 1 deficiency Hyperargininemia
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10062695 Arginase deficiency PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Completed) PT (Completed)
    Trial results: View results
    EudraCT Number: 2018-004159-19 Sponsor Protocol Number: 2018-00938 Start Date*: Information not available in EudraCT
    Sponsor Name:University Hospital Basel
    Full Title: Use of Copeptin Measurement after Arginine Infusion for the Diagnosis of Diabetes Insipidus - the CARGOx Study
    Medical condition: Polyuria-polydipsia syndrome (PPS) is divided into the three main entities central (complete or partial) diabetes insipidus (DI), nephrogenic DI and primary polydipsia (PP).
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing) NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-004637-33 Sponsor Protocol Number: FMLD-IOTRA-20_FIIIA Start Date*: 2014-06-11
    Sponsor Name:Laboratorios Farmalider S.A.
    Full Title: Clinical trial phase III, multicenter, randomised, double-blind, double-dummy, parallel treatment design, active-controlled and placebo, to evaluate the analgesic efficacy and safety of ibuprofen a...
    Medical condition: Moderate to severe pain following dental surgery.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-003336-12 Sponsor Protocol Number: FatherTrials2015 Start Date*: 2016-03-23
    Sponsor Name:Universiteit Leiden
    Full Title: Father Trials: Hormonal Experiments on Prenatal and Postnatal Parenting
    Medical condition: There are no medical conditions or diseases under investigation
    Disease: Version SOC Term Classification Code Term Level
    18.1 10022891 - Investigations 10047146 Vasopressin LLT
    18.1 10022891 - Investigations 10033329 Oxytocin PT
    Population Age: Adults Gender: Male
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-004837-34 Sponsor Protocol Number: CAEB1102-300A Start Date*: 2019-06-18
    Sponsor Name:Aeglea Biotherapeutics, Inc.
    Full Title: PEACE (Pegzilarginase Effect on Arginase 1 Deficiency Clinical Endpoints): A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of the Efficacy and Safety of Pegzilarginase in Children and ...
    Medical condition: Arginase 1 Deficiency Hyperargininemia
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10062695 Arginase deficiency PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: AT (Completed) DE (Completed) FR (Completed) GB (GB - no longer in EU/EEA) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-002895-14 Sponsor Protocol Number: APD334-202 Start Date*: 2020-02-13
    Sponsor Name:Arena Pharmaceuticals Inc.
    Full Title: A Phase 2b, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Efficacy and Safety of Oral Etrasimod as Induction Therapy in Subjects with Moderately to S...
    Medical condition: Crohn's Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10017947 - Gastrointestinal disorders 10011401 Crohn's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Prematurely Ended) NO (Completed) GB (Prematurely Ended) GR (Prematurely Ended) PT (Prematurely Ended) FR (Completed) CZ (Prematurely Ended) SK (Prematurely Ended) NL (Completed) BG (Prematurely Ended) HU (Prematurely Ended) ES (Prematurely Ended) IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-001125-26 Sponsor Protocol Number: ORG322 Start Date*: 2006-08-04
    Sponsor Name:University of Aberdeen
    Full Title: A randomised controlled trial of oral l-arginine supplementation on platelet and endothelial function and walking distance in patients with peripheral arterial disease
    Medical condition: Peripheral arterial disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2013-000330-35 Sponsor Protocol Number: HS-2012-1 Start Date*: 2013-05-23
    Sponsor Name:Medizinische Universität Graz
    Full Title: Effects of Linagliptin on endothelial function and global arginine bioavailability ratio in coronary artery disease patients with early diabetes
    Medical condition: Diabetes mellitus Type 2
    Disease: Version SOC Term Classification Code Term Level
    14.1 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2015-004317-24 Sponsor Protocol Number: MN2015-1/A Start Date*: 2017-06-22
    Sponsor Name:AZIENDA OSPEDALIERO-UNIVERSITARIA CAREGGI
    Full Title: “A pilot study to assess Coronary Flow Reserve and post-vasodilatatory Myocardial Blood Flow (post-Dipi gMBF), measured by 13N-NH3 PET/CT, before and after a six months-long treatment with the AC...
    Medical condition: Hypertrophic Cardiomyopathy (primitive)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10020871 Hypertrophic cardiomyopathy PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2018-003987-29 Sponsor Protocol Number: APD334-303 Start Date*: 2019-06-25
    Sponsor Name:Arena Pharmaceuticals Inc. a wholly owned subsidiary of Pfizer Inc.
    Full Title: An Open-Label Extension Study of Etrasimod in Subjects with Moderately to Severely Active Ulcerative Colitis
    Medical condition: Ulcerative Colitis
    Disease: Version SOC Term Classification Code Term Level
    20.1 10017947 - Gastrointestinal disorders 10045365 Ulcerative colitis LLT
    20.1 10017947 - Gastrointestinal disorders 10045366 Ulcerative colitis, unspecified LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Trial now transitioned) BE (Trial now transitioned) NL (Ongoing) CZ (Trial now transitioned) EE (Ongoing) FR (Trial now transitioned) LV (Completed) HU (Trial now transitioned) DE (Trial now transitioned) DK (Completed) AT (Completed) BG (Trial now transitioned) PL (Trial now transitioned) PT (Trial now transitioned) LT (Trial now transitioned) ES (Ongoing) HR (Completed) IT (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2010-018781-23 Sponsor Protocol Number: 2917800009 Start Date*: Information not available in EudraCT
    Sponsor Name:Top Institute Food and Nutrition
    Full Title: Diagnose of GH-deficiency: comparing the dietary-protein test with conventional Growth Hormone Stimulation Tests
    Medical condition: To investigate if there is a correlation between the peak GH concentrations after ingestion of gelatin protein and the peak GH concentrations after the two standard tests (GHST) in order to discrim...
    Disease: Version SOC Term Classification Code Term Level
    12.1 10056438 Growth hormone deficiency LLT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-004592-35 Sponsor Protocol Number: 6836 Start Date*: 2010-06-16
    Sponsor Name:Barts Health NHS Trust
    Full Title: A Randomised Stratified Multicentre Phase II Clinical Trial of Single-Agent ADI-PEG 20 (Pegylated Arginine Deiminase) in Patients with Malignant Pleural Mesothelioma.
    Medical condition: Mesothelioma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-005797-44 Sponsor Protocol Number: CL2-05985-005 Start Date*: 2007-03-14
    Sponsor Name:Institut de Recherches Internationales Servier
    Full Title: Efficacy and safety of the fixed oral low-dose perindopril arginine 3.5 mg/amlodipine 2.5 mg combination compared with each component (perindopril arginine 3.5 mg and amlodipine 2.5 mg) and with pe...
    Medical condition: Essential arterial hypertension
    Disease: Version SOC Term Classification Code Term Level
    8.1 10020775 Hypertension arterial LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Completed) FR (Completed) HU (Completed) LV (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 29 06:47:53 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA